Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease

JAMA. 2002 Jul 17;288(3):311; author reply 312-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiparkinson Agents / pharmacology*
  • Benzothiazoles
  • Brain / diagnostic imaging*
  • Brain / drug effects
  • Cocaine / analogs & derivatives
  • Dopamine Agonists / pharmacology*
  • Dopamine Plasma Membrane Transport Proteins
  • Humans
  • Membrane Glycoproteins*
  • Membrane Transport Proteins / metabolism
  • Nerve Tissue Proteins / metabolism
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / drug therapy*
  • Pramipexole
  • Radiopharmaceuticals
  • Thiazoles / pharmacology*
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Antiparkinson Agents
  • Benzothiazoles
  • Dopamine Agonists
  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Radiopharmaceuticals
  • Thiazoles
  • 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane
  • Pramipexole
  • Cocaine